Carfilzomib Plus Belinostat in Relapsed/Refractory Non-Hodgkin Lymphoma Subtypes: A Phase 1 Study
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2018
Price : $35 *
At a glance
- Drugs Belinostat (Primary) ; Carfilzomib (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions
- 23 Jan 2018 Status changed from active, no longer recruiting to completed.
- 31 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 20 Oct 2014 Planned End Date changed from 1 Apr 2020 to 1 Jan 2018 as reported by ClinicalTrials.gov.